Evidence map›Paper›PMID 27245592›Full record

ArticleJournal of neurovirology2016

Utility of a brief computerized battery to assess HIV-associated neurocognitive impairment in a resource-limited setting.

Nirupama Yechoor, Sheri L Towe, Kevin R Robertson, Daniel Westreich, Noeline Nakasujja, Christina S Meade

Open access · greenAbstract read
In one paragraph

Article in Journal of neurovirology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 4 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 4 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Nirupama YechoorDuke Global Health Institute, Duke University, Box 90519, Durham, NC, 27708, USA.
Sheri L ToweDuke Global Health Institute, Duke University, Box 90519, Durham, NC, 27708, USA.
Kevin R RobertsonDepartment of Neurology, Physicians Office Building, 170 Manning Drive, UNC-Chapel Hill, Chapel Hill, NC, 27599, USA.
Daniel WestreichDuke Global Health Institute, Duke University, Box 90519, Durham, NC, 27708, USA.
Noeline NakasujjaDepartment of Psychiatry, College of Health Sciences, Makerere University, Kampala, Uganda.
Christina S MeadeDuke Global Health Institute, Duke University, Box 90519, Durham, NC, 27708, USA. christina.meade@duke.edu.
Duke Institute for Health Innovation · USUniversity of North Carolina at Chapel Hill · USDuke University · USMakerere University · UG

Funding

Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Neurobehavioral and fMRI Research in HIV Infection and Cocaine DependenceK23DA028660 · NIDA · DUKE UNIVERSITY · PI MEADE, CHRISTINA S · 2010 to 2014
$825k
NIAID NIH HHS P30 AI064518NIDA NIH HHS K23 DA028660
6 · The paper itself

Abstract

Despite the persistently high prevalence of neurocognitive impairment in HIV-positive patients, routine HIV care in many resource-limited settings does not include neuropsychological assessment. The objective of this study was to examine the utility of a brief computerized battery for identifying neurocognitive impairment in a busy HIV clinic in Uganda. Specifically, we compared performance on a gold standard neuropsychological exam to that on the CogState Brief Battery. In this cross-sectional study, 181 HIV-positive patients completed both assessment batteries in a randomized order. The primary outcome measures were neurocognitive impairment on the standard exam defined by the global deficit score and cumulative performance on the CogState Brief Battery. Sixty-nine participants (38 %) were classified as impaired on the standard neuropsychological exam, and participants who were classified as impaired performed significantly worse on CogState compared to those who were unimpaired (p < 0.001). CogState had adequate specificity but low sensitivity, suggesting that it may not be a clinically useful screening tool to identify patients who likely have neurocognitive impairment in Uganda. This study supports the feasibility of using a computerized battery for assessing neurocognitive impairment in HIV-positive patients in resource-limited settings, but additional research is needed to identify screening tools with higher sensitivity for use in HIV clinics.

Indexed as

Neuropsychological TestsAdultCognitive DysfunctionCross-Sectional StudiesDeveloping CountriesFemaleHIV InfectionsHumansMalePrevalenceSensitivity and SpecificitySeverity of Illness IndexUgandaAfricaComputerized assessmentHIV/AIDSNeuroAIDSNeurocognitive impairment

Identifiers

PMID27245592
PMCPMC5130618
OpenAlexW2408818023

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.